Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
- Gardasil 9 Vaccine Protects against Additional HPV Types
(Posted: 03/02/2015) - In a large randomized clinical trial, a new human papillomavirus (HPV) vaccine effectively prevented infection and disease caused by nine high-risk HPV types, including seven types that cause cervical and other cancers—five of which were not covered by the previously available HPV vaccines—and two types that cause genital warts.
- Two Drugs that Hit One Target Improve Survival in Women with Metastatic Breast Cancer
(Updated: 02/26/2015) - Combining two drugs that target the HER2 protein, trastuzumab (Herceptin®) and pertuzumab, with chemotherapy is a new treatment option for women with HER2-positive metastatic breast cancer, according to final results from a large clinical trial.
- Three-Drug Combination Benefits Some Patients with Relapsed Multiple Myeloma
(Posted: 01/09/2015) - Interim results from an international, randomized phase III trial suggest that adding carfilzomib (Kyprolis®) to a standard treatment improves outcomes for patients with multiple myeloma whose cancer has relapsed. Participants in the study who received carfilzomib plus lenalidomide (Revlimid®) and dexamethasone lived a median of 8.7 months longer without the disease getting worse than patients who received lenalidomide and dexamethasone alone.
- Combining Two Types of Targeted Therapy Improves Survival in Some Patients with Advanced Melanoma
(Posted: 01/06/2015) - In two phase III trials, patients with metastatic melanoma whose tumors have specific mutations in the BRAF gene lived longer following treatment with dabrafenib (Tafinlar®), a BRAF inhibitor, plus trametinib (Mekinist®), a MEK inhibitor, than following treatment with a BRAF inhibitor alone.
- Nivolumab Improves Overall Survival in Patients with Metastatic Melanoma without a BRAF Mutation
(Posted: 01/06/2015) - Results from an international phase III trial show that nivolumab (Opdivo®) improves overall survival compared with the chemotherapy drug dacarbazine in patients with metastatic melanoma whose tumors do not have a mutation in the BRAF gene.